Alex Phipps
Overview
Explore the profile of Alex Phipps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abegesah A, Oh D, Lim K, Fan C, Chen C, Kim C, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):23.
PMID: 39821700
Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of...
2.
Shahraz A, Penney M, Candido J, Opoku-Ansah G, Neubauer M, Eyles J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Jul;
13(10):1670-1681.
PMID: 39041713
AZD0171 (INN: Falbikitug) is being developed as a humanized monoclonal antibody (mAb), immunoglobulin G subclass 1 (IgG1), which binds specifically to the immunosuppressive human cytokine leukemia inhibitory factor (LIF) and...
3.
Lim K, Zhu X, Zhou D, Ren S, Phipps A
Clin Pharmacol Ther
. 2024 Jun;
116(2):315-327.
PMID: 38825990
Bispecific antibodies, by enabling the targeting of more than one disease-associated antigen or engaging immune effector cells, have both advantages and challenges compared with a combination of two different biological...
4.
Sawant-Basak A, Olabode D, Dai D, Vishwanathan K, Phipps A
Drug Metab Dispos
. 2024 Feb;
52(11):1196-1200.
PMID: 38383116
The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied in vitro and in clinic. Cytokine-mediated suppression of cytochrome P450 (CYP) or drug transporters may increase or...
5.
He J, Duval V, Jauslin P, Goncalves A, Abegesah A, Fan C, et al.
Clin Pharmacol Ther
. 2023 Oct;
114(6):1375-1386.
PMID: 37777827
Blockade of CTLA-4 by tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy provided increased antitumor activity and long-term survival benefits in first-line metastatic non-small cell lung cancer (mNSCLC) in the phase...
6.
Lim K, Abegesah A, Fan C, He J, Song X, Chen C, et al.
J Clin Pharmacol
. 2023 Jun;
63(11):1221-1231.
PMID: 37300457
A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab (STRIDE) has demonstrated a favorable benefit-risk profile in the phase 1/2 Study 22 trial (in patients with unresectable...
7.
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, Kowalski K, Chow-Maneval E, et al.
Cancer Chemother Pharmacol
. 2023 Mar;
91(3):239-246.
PMID: 36884068
Purpose: Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib...
8.
Hwang M, Fan C, Yue M, Zhou D, Paturel C, Andre P, et al.
J Clin Pharmacol
. 2023 Feb;
63(7):817-829.
PMID: 36852723
Monalizumab is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. The objectives of this analysis were to develop a population pharmacokinetic...
9.
Ball K, Dovedi S, Vajjah P, Phipps A
MAbs
. 2023 Feb;
15(1):2181016.
PMID: 36823042
Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates...
10.
Johnson M, Patel M, Phipps A, van der Schaar M, Boulton D, Gibbs M
CPT Pharmacometrics Syst Pharmacol
. 2023 Jan;
12(3):279-284.
PMID: 36717763
No abstract available.